Michael D. Offin, MD
Assistant Attending Physician
Lung Cancer; Mesothelioma; Targeted Therapy for Lung Cancer; Clinical Trials
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Offin accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Rutgers University- New Jersey Medical School
Internal Medicine – Hospital of the University of Pennsylvania
Medical Oncology - Memorial Sloan Kettering Cancer Center
Internal Medicine; Medical Oncology
I am a board-certified medical oncologist dedicated to caring for people with lung cancer, including non-small cell lung cancer, small cell lung cancer and mesothelioma. Finding out that you or a family member has a thoracic cancer can be overwhelming. My team and I will help you understand your diagnosis and find the best path forward. I am devoted to providing the highest level of care throughout my patient’s treatment with the goal of providing a personalized approach to improve outcomes and quality of life.
I care for people with lung cancers (including those patients whose tumors harbor a BRAF alteration) and mesotheliomas (including pleural and peritoneal disease) at the David H. Koch Center for Cancer Care at MSK in Manhattan as well as MSK Westchester in West Harrison, New York. I work together with a comprehensive team of cancer experts from various disciplines to ensure that all of my patients receive individualized and exceptional care.
My research focuses on using laboratory findings to design clinical trials that further the care of my patients. With precision medicine and immunotherapy, people with thoracic cancers, including those with advanced disease, may have several treatment and clinical trial options available. Through my research, and when caring for my patients, I endeavor to analyze available options with a constant eye on evaluating new treatments. I aim to bring the discoveries made by our laboratory researchers to the bedside for the benefit of my patients and beyond.
My team and I are here to help you understand your diagnosis and find the best path forward.
Awards and Honors
- Deans Award, Rutgers University
- Alpha Omega Alpha member
- Gold Humanism Honor Society member
- Conquer Cancer Foundation ASCO Merit Award (2018)
- Clinical Trials Investigated by Dr. Offin
- A Phase I Study of HPN536 in Patients with Advanced Cancers, including Mesothelioma, Pancreatic Cancer, and Ovarian Cancer, that Continue to Grow Despite Standard Therapy
- A Phase I Study of Pembrolizumab Immunotherapy plus Cryoablation for People with Inoperable Mesothelioma
- A Study of Nivolumab Immunotherapy and Chemotherapy followed by Surgery for Pleural Mesothelioma
- Clinical Trials Co-Investigated by Dr. Offin
- A Phase I Study of a Targeted Cancer Vaccine (Galinpepimut-S) Combined with Nivolumab Immunotherapy in Patients with Persistent Pleural Mesothelioma
- A Phase I Study of CI-8993 Immunotherapy in People with Mesothelioma
- A Phase I Study of GDC-0084 with Radiation Therapy for People with PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
- A Phase I Study of Olaparib and Low-Dose Radiation Therapy for Small Cell Lung Cancer
- A Phase I Study of Pembrolizumab Immunotherapy and Radiation Therapy in People with Inoperable Pleural Mesothelioma
- A Phase I/II Study of MRTX1719 in People with Solid Tumors
- A Phase II Study Evaluating Stereotactic Body Radiotherapy plus Standard Therapy versus Standard Therapy Alone in Patients with Oligometastatic Breast Cancer or Lung Cancer
- A Phase II Study of Canakinumab with Chemotherapy, Radiation Therapy, and Durvalumab in People with Lung Cancer
- A Phase II Study to See if Durvalumab with Concurrent Radiation Therapy Can Prevent the Growth of Non-Small Cell Lung Cancer
- A Phase III Study of Durvalumab Immunotherapy with Chemotherapy as Initial Treatment for Advanced Pleural Mesothelioma
- A Phase III Study of Selpercatinib after Surgery or Radiation Therapy for RET Fusion-Positive Lung Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res. 2018 Jul 25. doi: 10.1158/1078-0432.CCR-18-1102. PMID: 30045933.
Sabari JK, Offin M [co-first author], Stephens D, Ni A, Lee A, Pavlakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Myers ML, Makhnin A, Leger Y, Yu HA, Paik PK, Chaft JE, Kris MG, Jeon JO, Borsu LA, Ladanyi M, Arcila ME, Hernandez J, Henderson S, Shaffer T, Garg K, DiPasquo D, Raymond CK, Lim LP, Li M, Hellmann MD, Drilon A, Riely GJ, Rusch VW, Jones DR, Rimner A, Rudin CM, Isbell JM, Li BT. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. J Natl Cancer Inst. 2018 Nov 28. doi: 10.1093/jnci/djy156. PMID: 30496436.
Suzawa K, Offin M [co-first author], Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin CM, Kris MG, Arcila ME, Lockwood WW, Drilon A, Ladanyi M, Somwar R. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin Cancer Res. 2018 Oct 23. doi: 10.1158/1078-0432.CCR-18-1640.PMID: 30352902.
Offin M, Liu D, Drilon A. Tumor-Agnostic Drug Development. Am Soc Clin Oncol Educ Book. 2018 May 23;(38):184-187. doi: 10.1200/EDBK_200831. PMID: 30231313.
Visit PubMed for a full listing of Dr. Offin’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael D. Offin discloses the following relationships and financial interests:
Provision of Services
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.